Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지

The Comparisons between RIA and CIA in CA19-9 Monitoring for Diagnosis of Pancreaticobiliary Tumors

  • Jung, Ha-Seung (Department of Clinical Laboratory Science, Dongnam Health College) ;
  • Kim, Dae-Sik (Department of Clinical Laboratory Science, Dongnam Health College)
  • 정하승 (동남보건대학 임상병리과) ;
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The CA(carbohydrate antigen)19-9 is complex protein that can be used as an important marker which aids the clinical diagnosis and prognosis of various pancreaticobiliary tumors. However, it was also reported that there were some CA19-9 positive patients with benign disease as using RIA method. The purpose of this study is to evaluate the clinical usefulness of serum level of CA19-9 with RIA(radioimmuno assay), CIA(chemiluminescence immuno assay), and conventional liver function tests. The correlation between CIA and RIA in CA19-9 of pancreatobiliary disease was 0.9833(P<0.01). Also, the correlations between CIA and RIA in CA19-9 of benign and malignant pancreaticobiliary tumor patients was 0.8714(P<0.01) and 0.9727(P<0.01) respectively. The correlation between CA19-9 and ALP was 0.5140(P<0.01) and CEA was 0.3385(P<0.05) as using CIA. The measurement of serum CA19-9 levels by CIA method may be useful in differentiating patients with malignant disease from those with benign disease in pancreaticobiliary tumors.

Keywords

References

  1. Afdhal NH, Long A, Tobbia I, O'Donoghue DP. Immunohistochemical CA19-9 in primary colonic polyps and polyps synchronous with colorectal cancer. Gut 1987. 28: 594-600. https://doi.org/10.1136/gut.28.5.594
  2. Alberts MB, Steinberg WM, Henry JP. Elivated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci. 1988. 33: 1223-1225. https://doi.org/10.1007/BF01536670
  3. Audisio RA, Verinesi P, Maisonneuve P, Chiappa A. Andreoni B, Bombardieri E, Geraghty JD. Clinical relevance of serogical markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncology 1996. 5: 49-53. https://doi.org/10.1016/S0960-7404(96)80001-6
  4. Collazos J, Gennolla J, Rubal A. CA19-9 in non-neoplastic liver disease. A climical and laboratory study. Clinca Chem Acta. 1992. 145: 145-151.
  5. Del Villano BC, Brennas S, Brock P. Radioimmunometric assay for a monoclonal antibody defined tumor marker CA19-9. Clin Chem. 1983. 29: 549-552.
  6. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA50 and CEA. Br J Cancer 1994. 70: 487-491. https://doi.org/10.1038/bjc.1994.332
  7. Ikeda Y, Mori M, Kido A. Immunohistochemical expression of carbohydrate antigen CA19-9 gastric carcinoma. AM J Gastroenterol. 1991. 86: 1163-1166.
  8. Ker CG, Chen JS, Lee KT. Assessment of serum and bile duct carcinoma. J Gastroenterol Hapatol. 1991. 6: 505-508. https://doi.org/10.1111/j.1440-1746.1991.tb00896.x
  9. Kim HJ, Myung SJ, Yown SY, Choi WB, Lee JH, Park CS, Youn GH, Kim SG, Nam SW, Yang SH, Seo DW, Lee SK, Kim MH, Min YI. Applications of individual value of CA19-9 according to the clinical bases in differentiation of pancreaticobiliary cancer; analysis using the receiver operating characteristic curve. Kor J Gatroenterol. 1998. 32: 648: 648-656.
  10. Koprowski H, Steplewski Z, Mitchell K. Colorectal carcinoma antigens detected by hybridoma antibodies. Som Cell Gene 1979. 5: 957-972. https://doi.org/10.1007/BF01542654
  11. Koprowski H, Herlyn M, Steplewsk Z. Specific antigen in serum of patients with colon carcinoma. Science 1981. 212: 53-55. https://doi.org/10.1126/science.6163212
  12. Koyahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I. Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 1995. 117: 616-620. https://doi.org/10.1016/S0039-6060(95)80003-4
  13. Lin JJ, Wang TH, Sung JL, Che DS. Carbohydrate antigen CA19-9: a valuable tumor marker of pancreatic cancer. J Formosan Med Assoc. 1985. 84: 828-835.
  14. Lundin J, Roberts P, Kuusel AP, Haglund C. The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. Br J cancer 1994. 69: 515-519.
  15. Maganani J, Nilsson B, Brockhaus M. The antigen of a tumor specific monoclonal antibody is a ganglioside containing sialylated lacto-N-fuco-pentose II. Fed Proc. 1982. 41: 89-96.
  16. Maganani J, Nilsson B, Brockhaus MA. Monoclonal antibodydefined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fuco-pentaose II. J Bio Chem. 1982. 257: 14365-14369.
  17. Myung SJ, Choi SM, Kim EO, Choi HS, Lee SK, Kim MH, Min YI, Ryu JS. The diagnostic value of CA19-9 in pancreaticobiliary disease. Kor J Gatroenterol. 1995. 27: 347-355.
  18. Ogawa M, Karasawa H, Kobayashi T. Effect of biliary tract obstruction and cholangitis in serum CA19-9 level. Jpn J Gastroentrol. 1985. 82: 1418-1422.
  19. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhave E. Multivariate analysis of six serum tumor markers (CEA, CA50, CA242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res. 1995. 15: 2731-2736.
  20. Satake K, Takeuchi T. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994. 9: 720-723. https://doi.org/10.1097/00006676-199411000-00008
  21. Schmiegel W. Tumormarkers in pancreatic cancer current concepts. Hapatogastroenterology 1989. 36: 446-449.
  22. Shimono R, Mori M, Akazawa K, Adachi Y, Sgimachi K. Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma. Am J Gastroenterol. 1994. 89: 1: 101 -105.
  23. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastrol. 1989. 85: 4: 350-355.
  24. Turtel PS, Kreel I. Israel J. Elevated CA19-9 in a case of Mizzi's syndrome. Am J Gastroenterol. 1992. 87: 3: 355-357.
  25. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, Kurimoto K, Ohashi Y. Prognostic values of preoperative and postoperative CEA and CA19-9 levels in pancreatic cancer. Pancreas 1994. 9: 735-739. https://doi.org/10.1097/00006676-199411000-00011